Cargando…
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
BACKGROUND: Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732716/ https://www.ncbi.nlm.nih.gov/pubmed/29262550 http://dx.doi.org/10.18632/oncotarget.21602 |
_version_ | 1783286763194679296 |
---|---|
author | Oya, Yuko Yoshida, Tatsuya Kuroda, Hiroaki Mikubo, Masashi Kondo, Chiaki Shimizu, Junichi Horio, Yoshitsugu Sakao, Yukinori Hida, Toyoaki Yatabe, Yasushi |
author_facet | Oya, Yuko Yoshida, Tatsuya Kuroda, Hiroaki Mikubo, Masashi Kondo, Chiaki Shimizu, Junichi Horio, Yoshitsugu Sakao, Yukinori Hida, Toyoaki Yatabe, Yasushi |
author_sort | Oya, Yuko |
collection | PubMed |
description | BACKGROUND: Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However, the association between the clinical parameters and efficacy of nivolumab remains unclear in advanced NSCLC patients. RESULTS: Among 124 patients, 108 (88%) were performance status (PS) 0 to 1. PD-L1 expression was assessed in 89 patients, with 51 (57%) patients having PD-L1 positive expression. In all patients, the objective response rate (ORR) in patients with elevated CRP levels (≥ 1 mg/dl) was significantly worse than those without elevated CRP levels (< 1 mg/dl) (8.3 vs 23.4%, p = 0.0180). The PS (≥ 2), smoking index (< 400), CRP levels (≥ 1 mg/dl) and LDH (≥ 245 IU/L) were significantly associated with a shorter PFS and OS in patients treated with nivolumab. Multivariate analyses showed that the PS (≥ 2), smoking index (< 400), CRP levels (≥ 1 mg/dl) and LDH (≥ 245 IU/L) and PD-L1 expression were significant factors associated with a longer PFS of nivolumab. MATERIALS AND METHODS: We retrospectively analyzed 124 patients who received nivolumab as a subsequent treatment. The patient characteristics, laboratory data at baseline (C-reactive protein [CRP] and lactate dehydrogenase [LDH]), PD-L1 expression, nivolumab response, progression-free survival (PFS), and overall survival (OS) were evaluated. CONCLUSIONS: Clinical parameters, such as PS, serum CRP, serum LDH, and smoking status, were significantly associated with the response duration and survival in patients treated with nivolumab. |
format | Online Article Text |
id | pubmed-5732716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57327162017-12-19 Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer Oya, Yuko Yoshida, Tatsuya Kuroda, Hiroaki Mikubo, Masashi Kondo, Chiaki Shimizu, Junichi Horio, Yoshitsugu Sakao, Yukinori Hida, Toyoaki Yatabe, Yasushi Oncotarget Research Paper BACKGROUND: Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However, the association between the clinical parameters and efficacy of nivolumab remains unclear in advanced NSCLC patients. RESULTS: Among 124 patients, 108 (88%) were performance status (PS) 0 to 1. PD-L1 expression was assessed in 89 patients, with 51 (57%) patients having PD-L1 positive expression. In all patients, the objective response rate (ORR) in patients with elevated CRP levels (≥ 1 mg/dl) was significantly worse than those without elevated CRP levels (< 1 mg/dl) (8.3 vs 23.4%, p = 0.0180). The PS (≥ 2), smoking index (< 400), CRP levels (≥ 1 mg/dl) and LDH (≥ 245 IU/L) were significantly associated with a shorter PFS and OS in patients treated with nivolumab. Multivariate analyses showed that the PS (≥ 2), smoking index (< 400), CRP levels (≥ 1 mg/dl) and LDH (≥ 245 IU/L) and PD-L1 expression were significant factors associated with a longer PFS of nivolumab. MATERIALS AND METHODS: We retrospectively analyzed 124 patients who received nivolumab as a subsequent treatment. The patient characteristics, laboratory data at baseline (C-reactive protein [CRP] and lactate dehydrogenase [LDH]), PD-L1 expression, nivolumab response, progression-free survival (PFS), and overall survival (OS) were evaluated. CONCLUSIONS: Clinical parameters, such as PS, serum CRP, serum LDH, and smoking status, were significantly associated with the response duration and survival in patients treated with nivolumab. Impact Journals LLC 2017-10-07 /pmc/articles/PMC5732716/ /pubmed/29262550 http://dx.doi.org/10.18632/oncotarget.21602 Text en Copyright: © 2017 Oya et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Oya, Yuko Yoshida, Tatsuya Kuroda, Hiroaki Mikubo, Masashi Kondo, Chiaki Shimizu, Junichi Horio, Yoshitsugu Sakao, Yukinori Hida, Toyoaki Yatabe, Yasushi Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer |
title | Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer |
title_full | Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer |
title_fullStr | Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer |
title_full_unstemmed | Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer |
title_short | Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer |
title_sort | predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732716/ https://www.ncbi.nlm.nih.gov/pubmed/29262550 http://dx.doi.org/10.18632/oncotarget.21602 |
work_keys_str_mv | AT oyayuko predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT yoshidatatsuya predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT kurodahiroaki predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT mikubomasashi predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT kondochiaki predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT shimizujunichi predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT horioyoshitsugu predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT sakaoyukinori predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT hidatoyoaki predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer AT yatabeyasushi predictiveclinicalparametersfortheresponseofnivolumabinpretreatedadvancednonsmallcelllungcancer |